Evidence map›Paper›PMID 38405312›Full record

ArticleAdvances in radiation oncology2024

Pretrial Quality Assurance for Hypofractionated Salvage Radiation Therapy After Prostatectomy in the Multi-Institutional PERYTON-trial.

Floor H E Staal, Kelvin Ng Wei Siang, Charlotte L Brouwer, Jorinde Janssen, Tom C G Budiharto, Dorien M A D Haverkort, Birgit Hollmann, Inge Jacobs, Marianne A A De Jong, Mariska A E van de Sande and 6 more

Open access · goldAbstract read
In one paragraph

Article in Advances in radiation oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Floor H E StaalDepartment of Radiation Oncology, University Medical Centre Groningen, Groningen, The Netherlands.
Kelvin Ng Wei SiangDepartment of Radiation Oncology, University Medical Centre Groningen, Groningen, The Netherlands.
Charlotte L BrouwerDepartment of Radiation Oncology, University Medical Centre Groningen, Groningen, The Netherlands.
Jorinde JanssenDepartment of Radiation Oncology, University Medical Centre Groningen, Groningen, The Netherlands.
Tom C G BudihartoDepartment of Radiation Oncology, Catharina Hospital, Eindhoven, The Netherlands.
Dorien M A D HaverkortRadiotherapiegroep Arnhem/Deventer, Arnhem, The Netherlands.
Birgit HollmannDepartment of Radiation Oncology, HAGA Ziekenhuis, Den Haag, The Netherlands.
Inge JacobsZuidwest Radiotherapy Institute Vlissingen/Roosendaal, Vlissingen, The Netherlands.
Marianne A A De JongRadiotherapy Institute Friesland, Leeuwarden, The Netherlands.
Mariska A E van de SandeInstitute Verbeeten, Tilburg, The Netherlands.
Ben G L VannesteDepartment of Radiation Oncology, MAASTRO Clinic, GROW-School for Oncology and Developmental Biology, Maastricht, The Netherlands.
Igle Jan De JongDepartment of Urology, University Medical Centre Groningen, Groningen, The Netherlands.
J Fred VerzijlbergenDepartment of Nuclear Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands.
Johannes A LangendijkDepartment of Radiation Oncology, University Medical Centre Groningen, Groningen, The Netherlands.
Robert Jan SmeenkDepartment of Radiation Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Shafak AluwiniDepartment of Radiation Oncology, University Medical Centre Groningen, Groningen, The Netherlands.
University Medical Center Groningen · NLRadboud University Nijmegen · NLHaga Hospital · NLInstituut Verbeeten · NLMaastro Clinic · NLRadiotherapeutisch Instituut Friesland · NLRadiotherapiegroep · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The PERYTON trial is a multicenter randomized controlled trial that will investigate whether the treatment outcome of salvage external beam radiation therapy (sEBRT) will be improved with hypofractionated radiation therapy. A pretrial quality assurance (QA) program was undertaken to ensure protocol compliance within the PERYTON trial and to assess variation in sEBRT treatment protocols between the participating centers. Methods and Materials: Completion of the QA program was mandatory for each participating center (N = 8) to start patient inclusion. The pretrial QA program included (1) a questionnaire on the center-specific sEBRT protocol, (2) a delineation exercise of the clinical target volume (CTV) and organs at risk, and (3) a treatment planning exercise. All contours were analyzed using the pairwise dice similarity coefficient (DSC) and the 50th and 95th percentile Hausdorff distance (HD50 and HD95, respectively). The submitted treatment plans were reviewed for protocol compliance. Results: The results of the questionnaire showed that high-quality, state-of-the-art radiation therapy techniques were used in the participating centers and identified variations of the sEBRT protocols used concerning the position verification and preparation techniques. The submitted CTVs showed significant variation, with a range in volume of 29 cm Conclusions: The pretrial QA of the PERYTON trial demonstrated that high-quality, but variable, radiation techniques were used in the 8 participating centers. The treatment planning exercise confirmed that the dose constraints of the PERYTON protocol were feasible for all participating centers. The observed variation in CTV delineation led to agreement on a new (image-based) delineation guideline to be used by all participating centers within the PERYTON trial.

Identifiers

PMID38405312
PMCPMC10885595
OpenAlexW4386815920

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.